Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Revolution Medicines, Inc. (RVMD) AI Forecast

Our AI analyzed Revolution Medicines, Inc.. Create a free account to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$RVMD Neutral Signal Full forecast available
Sign Up Free

Revolution Medicines, Inc. (RVMD) Stock Forecast 2025

Revolution Medicines, Inc. (RVMD) AI Stock Price Forecast & Investment Analysis

Revolution Medicines, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Revolution Medicines, Inc. (RVMD) - Comprehensive Stock Analysis & Investment Research

Deep dive into Revolution Medicines, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on June 25, 2026, 6:24 a.m. (UTC)

Revolution Medicines, Inc. Investment Summary

When evaluating whether Revolution Medicines, Inc. (RVMD) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Revolution Medicines, Inc. (RVMD) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $34 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Revolution Medicines, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Revolution Medicines, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Revolution Medicines, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Revolution Medicines, Inc.

Sign Up Free
Corporate Identity

Revolution Medicines, Inc. (Stock Symbol: RVMD) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Revolution Medicines, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Revolution Medicines, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Revolution Medicines, Inc....

Unlock Full Company Profile

Get complete details about Revolution Medicines, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Revolution Medicines, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Revolution Medicines, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Revolution Medicines, Inc....

Unlock Financial Analysis

Get complete financial metrics for Revolution Medicines, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Revolution Medicines, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Revolution Medicines, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Revolution Medicines, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-1072 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 6.80 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Revolution Medicines, Inc. (RVMD) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Revolution Medicines, Inc. stock analysis.

Deep dive into Revolution Medicines, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Revolution Medicines, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Revolution Medicines, Inc.:

P/B Ratio 22.62x
Market Cap $33.93B
Book Value/Share $7.49
FCF/Share $-5.35
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Revolution Medicines, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Revolution Medicines, Inc.: An ROE of -5.2% indicates room for improvement in shareholder value creation.

ROE -5.2%
ROA -3.5%
ROIC -4.3%
Operating Margin -182.6%
Net Margin -169.1%
EBT Margin -174.9%
Tax Rate 3.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Revolution Medicines, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Revolution Medicines, Inc.: A current ratio of 6.80 indicates strong liquidity.

Current Ratio 6.80x
D/E Ratio 0.50x
Financial Leverage 1.50x
Interest Coverage -3116.4x
Working Capital $1.68B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Revolution Medicines, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Revolution Medicines, Inc.: Free cash flow of $-1072M indicates cash challenges that need attention.

Operating Cash Flow -$112M
Free Cash Flow -$1.07B
Capital Spending -$960M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Revolution Medicines, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Revolution Medicines, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Revolution Medicines, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Revolution Medicines, Inc.:

Income Statement
Operating Income -$84M
Net Income -$78M
R&D Expense $110M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 1968%
Cash & Short-term Investments 441%
Total Liabilities 754%
Short-term Debt 209%
Dividend & Shareholder Information
Shares Outstanding 200M
Growth Metrics (YoY)
Net Income Growth -169.1%

Latest Revolution Medicines, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Revolution Medicines, Inc. (RVMD) stock price and investment outlook.

📰 We are currently updating our news feed for Revolution Medicines, Inc.. Check back soon for the latest market analysis and company updates.

Revolution Medicines, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Revolution Medicines, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $167M x 1.9x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $1M x x
Arcellx, Inc. ACLX ██% $6.73B x 16.7x
Alpha Cognition Inc. ACOG ██% $143M x 2.5x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.02B 12.2x 5.2x
Adaptive Biotechnologies Corp ADPT ██% $3.09B x 14.3x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $112M 1.7x x
Agentix Corp. AGTX ██% $680K x x
Aim Immunotech Inc. AIM ██% $10M x 4.9x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $199M x 19.1x
Aligos Therapeutics, Inc. ALGS ██% $34M x 1.1x
Allogene Therapeutics, Inc. ALLO ██% $708M x 2.5x
Alvotech ALVO ██% $1.15B x x
Amgen Inc AMGN ██% $189.67B 24.3x 20.6x
Apogee Therapeutics, Inc. APGE ██% $9.94B x x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $52.76B x x
Armata Pharmaceuticals, Inc. ARMP ██% $268M x x
Artiva Biotherapeutics, Inc. ARTV ██% $453M x 5.2x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $90M x x
Atyr Pharma Inc ATYR ██% $55M x 1.0x
Aura Biosciences, Inc. AURA ██% $728M x 6.8x
Autolus Therapeutics Plc AUTL ██% $423M x 3.9x
Anavex Life Sciences Corp. AVXL ██% $237M x 1.9x
Bioatla, Inc. BCAB ██% $6M x x
Biocardia, Inc. BCDA ██% $16M x x
Brainstorm Cell Therapeutics Inc. BCLI ██% $10M x x
Biocryst Pharmaceuticals Inc BCRX ██% $2.54B x x
Black Diamond Therapeutics, Inc. BDTX ██% $107M x 1.0x
Beam Therapeutics Inc. BEAM ██% $3.48B x 3.0x
Biogen Inc. BIIB ██% $29.38B 21.4x 1.6x
Biontech Se BNTX ██% $22.81B x x
Cabaletta Bio, Inc. CABA ██% $494M x 4.8x
Candel Therapeutics, Inc. CADL ██% $679M x 4.9x
C4 Therapeutics, Inc. CCCC ██% $442M x 1.9x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $7M x 1.2x
Cero Therapeutics Holdings, Inc. CERO ██% $450K x x
Cullinan Therapeutics, Inc. CGEM ██% $1.08B x 3.0x
Compugen Ltd CGEN ██% $190M 2.7x 1.9x
Cg Oncology, Inc. CGON ██% $6.05B x 5.5x
Cognition Therapeutics Inc CGTX ██% $91M x 3.1x
Coherus Oncology, Inc. CHRS ██% $234M 1.3x 3.0x
Calidi Biotherapeutics, Inc. CLDI ██% $3M x 0.6x
Cellectis S.A. CLLS ██% $281M x x
Compass Therapeutics, Inc. CMPX ██% $364M x 2.0x
Mosaic Immunoengineering Inc. CPMV ██% $5M x x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $86M x 2.5x
Cardiol Therapeutics Inc. CRDL ██% $119M x x
Curis Inc CRIS ██% $14M x 1.1x
Crispr Therapeutics Ag CRSP ██% $5.16B x 2.8x
Champions Oncology, Inc. CSBR ██% $85M x 19.9x
Cel Sci Corp CVM ██% $17M x 2.5x
Dbv Technologies S.A. DBVT ██% $923M x 5.5x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $600M x 1.4x
Denali Therapeutics Inc. DNLI ██% $3.94B x 4.3x
Precision Biosciences Inc DTIL ██% $174M x 2.3x
Dyadic International Inc DYAI ██% $27M x x
Editas Medicine, Inc. EDIT ██% $430M x 97.5x
Eloxx Pharmaceuticals, Inc. ELOX ██% $8M x x
Elutia Inc. ELUT ██% $42M 0.9x 1.9x
Engene Therapeutics Inc. ENGN ██% $117M x 0.5x
Entera Bio Ltd. ENTX ██% $72M x 6.7x
Viskase Holdings, Inc. ENZN ██% $35M x 0.2x
Estrella Immunopharma, Inc. ESLA ██% $41M x x
Evaxion A/S EVAX ██% $28M x x
Exelixis, Inc. EXEL ██% $13.41B 16.1x 6.9x
Exozymes Inc. EXOZ ██% $61M x 39.6x
Fate Therapeutics Inc FATE ██% $240M x 1.3x
4d Molecular Therapeutics, Inc. FDMT ██% $607M x 1.3x
Fennec Pharmaceuticals Inc. FENC ██% $359M x 9.5x
Finch Therapeutics Group, Inc. FNCH ██% $12M 0.5x 0.9x
Finch Therapeutics Group, Inc. FNCHQ ██% $12M 0.5x 0.8x
Futuretech Ii Acquisition Corp. FTII ██% $52M x x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $155.45B 16.9x 6.6x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.76B x 3.4x
Genenta Science S.P.A. GNTA ██% $44M x 3.5x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $260K x x
Greenland Mines Ltd GRML ██% $34M x 0.7x
Halozyme Therapeutics, Inc. HALO ██% $8.43B 24.2x 38.4x
Humacyte, Inc. HUMA ██% $188M x 16.2x
Immunitybio, Inc. IBRX ██% $8.17B x x
Inhibikase Therapeutics, Inc. IKT ██% $247M x 1.5x
Imagenebio, Inc. IMA ██% $68M x 0.6x
Immunocore Holdings Plc IMCR ██% $1.52B x 3.9x
Immatics N.V. IMTX ██% $1.34B x x
Immunovant, Inc. IMVT ██% $7.79B x 9.1x
In8bio, Inc. INAB ██% $15M x 0.6x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $58M x x
Inmune Bio, Inc. INMB ██% $36M x 1.8x
Intensity Therapeutics, Inc. INTS ██% $10M x 1.0x
Iovance Biotherapeutics, Inc. IOVA ██% $1.86B x 2.6x
Century Therapeutics, Inc. IPSC ██% $412M x 1.6x
Invivyd, Inc. IVVD ██% $264M x 1.3x
Jasper Therapeutics, Inc. JSPR ██% $14M x 4.0x
Kalaris Therapeutics, Inc. KLRS ██% $100M x 1.5x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.30B x 20.5x
Krystal Biotech, Inc. KRYS ██% $10.21B 45.4x 8.0x
Kymera Therapeutics, Inc. KYMR ██% $8.21B x 5.3x
Kyverna Therapeutics, Inc. KYTX ██% $510M x 2.6x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $312M x 5.8x
Lenz Therapeutics, Inc. LENZ ██% $180M x 0.7x
Atyr Pharma Inc LIFE ██% $1.81B x 31.2x
Liminatus Pharma, Inc. LIMN ██% $5M x x
Leonabio, Inc. LONA ██% $79M x 1.6x
Lexeo Therapeutics, Inc. LXEO ██% $362M x 1.6x
Maze Therapeutics, Inc. MAZE ██% $1.46B x 4.3x
Mesoblast Ltd MESO ██% $2.00B x x
Meiragtx Holdings Plc MGTX ██% $1.09B x x
Metagenomi Therapeutics, Inc. MGX ██% $47M x 0.3x
Molecular Partners Ag MOLN ██% $154M x x
Moderna, Inc. MRNA ██% $24.22B x 3.3x
Neurocrine Biosciences Inc NBIX ██% $16.24B 24.3x 4.8x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $290M x 4.1x
Novavax Inc NVAX ██% $1.48B x x
Ocugen, Inc. OCGN ██% $467M x 80.4x
Outlook Therapeutics, Inc. OTLK ██% $205M x x
Palisade Bio, Inc. PALI ██% $325M x 2.6x
Passage Bio, Inc. PASG ██% $20M x 1.7x
Vaxcyte, Inc. PCVX ██% $7.50B x 2.5x
Biomx Inc. PHGE ██% $5M x x
Pluri Inc. PLUR ██% $22M x x
Protalix Biotherapeutics, Inc. PLX ██% $173M 11.3x 2.6x
Pharmacyte Biotech, Inc. PMCB ██% $8M x 0.2x
Prime Medicine, Inc. PRME ██% $585M x 7.6x
Prokidney Corp. PROK ██% $544M x x
Pelthos Therapeutics Inc. PTHS ██% $99M x 2.8x
Qiagen N.V. QGEN ██% $8.07B x 2.1x
Quince Therapeutics, Inc. QNCX ██% $19M 2.2x 1.2x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $909M x 4.3x
Repligen Corp RGEN ██% $7.13B 138.7x 3.4x
Regenxbio Inc. RGNX ██% $514M x 24.4x
Relay Therapeutics, Inc. RLAY ██% $3.80B x 5.9x
Revolution Medicines, Inc. RVMD ██% $33.93B x 22.6x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.68B x 1.6x
Sab Biotherapeutics, Inc. SABS ██% $296M x 1.3x
Sana Biotechnology, Inc. SANA ██% $904M x 7.6x
Scilex Holding Co SCLX ██% $48M x x
Scinai Immunotherapeutics Ltd. SCNI ██% $1M x 0.2x
Sangamo Therapeutics, Inc SGMO ██% $27M x x
Solid Biosciences Inc. SLDB ██% $865M x 2.3x
Silexion Therapeutics Corp SLXN ██% $3M x 9.9x
Senti Biosciences Holdings, Inc. SNTI ██% $29M x 11.2x
Scholar Rock Holding Corp SRRK ██% $6.11B x 22.1x
Surrozen, Inc./De SRZN ██% $286M x x
Sutro Biopharma, Inc. STRO ██% $502M x x
Protara Therapeutics, Inc. TARA ██% $220M x 1.2x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.85B x 8.2x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $60M x 0.6x
Bio-Techne Corp TECH ██% $9.17B 83.7x 4.4x
Tectonic Therapeutic, Inc. TECX ██% $592M x 2.6x
Instil Bio, Inc. TIL ██% $52M x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $164M x 1.5x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.99B x 9.4x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $40M x x
Twist Bioscience Corp TWST ██% $5.64B x 12.4x
Voyager Acquisition Corp./Cayman Islands VACH ██% $541M 80.4x x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $501M x x
Vericel Corp VCEL ██% $2.13B 99.3x 6.0x
Vir Biotechnology, Inc. VIR ██% $1.66B x 2.0x
Vivosim Labs, Inc. VIVS ██% $3M x 0.7x
Vor Biopharma Inc. VOR ██% $800M x x
Vaxart, Inc. VXRT ██% $122M 3.3x 1.3x
Voyager Therapeutics, Inc. VYGR ██% $225M x 1.3x
Windtree Therapeutics Inc /De/ WINT ██% $540K x x
X4 Pharmaceuticals, Inc XFOR ██% $384M x 2.3x
Zeo Scientifix, Inc. ZEOX ██% $13M x 18.1x
Zivo Bioscience, Inc. ZIVO ██% $14M x x
Zura Bio Ltd ZURA ██% $405M x 1.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Revolution Medicines, Inc. Stock Forecast

How accurate are Revolution Medicines, Inc. stock predictions?

Our AI model shows a 5% Spearman correlation coefficient for RVMD predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Revolution Medicines, Inc. stock price forecasts?

Our analysis considers Revolution Medicines, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Revolution Medicines, Inc. a good investment in 2025?

Based on our AI analysis, Revolution Medicines, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Revolution Medicines, Inc. forecasts updated?

Revolution Medicines, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Revolution Medicines, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...